Is Enasidenib a targeted drug?

Enasidenib (Enasidenib) is a targeted therapy that meets the needs of patients with relapsed or refractory acute myeloid leukemia with IDH2 mutations. The use of ensidipine is associated with complete remission and a reduced need for red blood cell and platelet transfusions in some patients.

Ensidipine is not considered a traditional chemotherapy ("chemotherapy") agent. Ensidipine is an oral targeted therapy for acute myeloid leukemia (AML), a type of blood cancer. Enasidenib, the ingredient in Ensidipine, works by blocking isocitrate dehydrogenase-2 (IDH2). Doctors will test the patient's blood or bone marrow through relevant examinations to see if they have IDH2 mutations and whether they are suitable for ensidipine treatment. Blocking IDH2 helps blood cells in the bone marrow grow into healthy, functioning red blood cells, white blood cells and platelets. The body needs these healthy cells to carry oxygen, fight infection, and help prevent bleeding.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.